RDUS Radius Health, Inc. gains 17% Jul 10, 2017

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its lead product comprises Abaloparatide-SC, a novel synthetic peptide analog of parathyroid hormone-related protein, which has been completed Phase III clinical development for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch that has been completed Phase II clinical trial, which is used as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer and other estrogen receptor mediated oncology applications, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator that is in preclinical stage for the treatment of breast cancer or other conditions. It has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; and Lonza Group Ltd., as well as clinical collaboration with Novartis Pharmaceuticals. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. http://www.priceseries.com/trade/RDUS-Radius-Health-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2017061220170710.html